Dr. Jianwei Lu 陆建伟
Chief Physician, Associate Professor
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of digestive and respiratory tract tumors, with a focus on individualized therapy for gastrointestinal cancers.
Dr. Lu holds an MD and a PhD in Integrative Medicine. Since 1988, Dr. Lu has worked at Jiangsu Cancer Hospital, specializing in medical oncology. Dr. Lu completed training in tumor chemotherapy at Aichi Cancer Center, Japan (2002–2003). Dr. Lu has led multiple provincial and national research projects, published over 80 papers, and received several science and technology progress awards.
Professional roles
- Vice Chair, Multicentric and Unknown Primary Tumor Committee, China Anti-Cancer Association
- Standing Committee Member, Cancer Nutrition and Supportive Care Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Tumor Chemotherapy and Biotherapy Branch, Jiangsu Medical Association
- Member, Gastric Cancer Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Lu Jianwei). Papers usually list the name as Jianwei Lu or Lu J.
Selected publications
59 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Oncol, 2022 (senior author): Clinicopathological Features and Postoperative Survival Analysis of Gastric Carcinoma with Neuroendocrine Differentiation. PubMed 36035314
- J Gastrointest Oncol, 2021 (senior author): Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer. PubMed 35070406
- Aging (Albany NY), 2021 (senior author): Linc00941 regulates esophageal squamous cell carcinoma via functioning as a competing endogenous RNA for miR-877-3p to modulate PMEPA1 expression. PubMed 34254950
- Cancer Manag Res, 2021 (senior author): IL-33 Promotes the Growth of Non-Small Cell Lung Cancer Cells Through Regulating miR-128-3p/CDIP1 Signalling Pathway. PubMed 33737835
- Aging (Albany NY), 2021 (senior author): Down-regulation of estrogen-related receptor alpha (ERRα) inhibits gastric cancer cell migration and invasion in vitro and in vivo. PubMed 33591949
- Onco Targets Ther, 2020 (senior author): KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. PubMed 33335401
- Cancer Manag Res, 2020 (senior author): A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. PubMed 32982442
- Oncogene, 2020 (senior author): LncRNA KTN1-AS1 promotes the progression of non-small cell lung cancer via sponging of miR-130a-5p and activation of PDPK1. PubMed 32820252
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion